Abstract
The International League of Associations for Rheumatology (ILAR) has been meeting with the World Health Organization (WHO) on a regular basis to discuss issues of mutual interest. Over the last few years these meetings have focused on the development of outcome measures in the rheumatic diseases, principally driven through OMERACT (Outcome Measures for Arthritis Clinical Trials). OMERACT has now held five meetings addressing a number of important areas in rheumatology, including clinical and imaging outcome measures, health economics and drug safety. The advantage of the WHO/ILAR Task Force Meeting has been to ratify these measures and allow them to be promulgated widely around the world.

This publication has 0 references indexed in Scilit: